04:45 PM EDT, 08/12/2024 (MT Newswires) -- Immunome ( IMNM ) reported Q2 net loss late Monday of $0.60 per diluted share, widening from $0.46 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.39.

Revenue for the quarter ended June 30 was $2.4 million, down from $4.3 million a year earlier. Analysts polled by Capital IQ expected $1.9 million.

The company said its cash, cash equivalents and marketable securities were $278.4 million at the end of June. It expects the current cash runway to extend into 2026.